We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
SNY Wins FDA Approval for Infilbray in Type 3 Gaucher Disease
Read MoreHide Full Article
Key Takeaways
Sanofi secured FDA approval for Infilbray, the first U.S. therapy for neurological symptoms of GD3.
Infilbray is an oral treatment approved for adults and pediatric GD3 patients weighing at least 15 kg.
The FDA approval is based on positive data from the phase III LEAP2MONO study.
Sanofi (SNY - Free Report) announced that the FDA has granted approval to Infilbray (venglustat), a once-daily oral medicine, to treat patients with type 3 Gaucher disease (GD3). With this approval, the drug becomes the first therapy in the United States to address the progressive neurological symptoms of GD3.
Infilbray is an oral glucosylceramide synthase inhibitor, indicated for the treatment of neurological manifestations of GD3 in adults and pediatric patients weighing at least 15 kg.
Gaucher disease is a rare genetic lysosomal disorder caused by a deficiency of the enzyme glucocerebrosidase, which leads to the buildup of glycosphingolipids in cells, especially in macrophages within the spleen, liver, bone marrow and lungs.Type 3 Gaucher disease is a chronic form of the disorder that affects both the body and the central nervous system.
Year to date, SNY’s shares have risen 1.2% compared with the industry’s 26.7% growth.
Image Source: Zacks Investment Research
Venglustat’s FDA Approval Backed by SNY’s Late-Stage Study
The FDA approval for Infilbray in GD3 is based on positive data from the phase III LEAP2MONO study, which evaluated Infilbray in patients aged 12 years and older with GD3 who were stable on enzyme replacement therapy (ERT) against Cerezyme (imiglucerase), an intravenous ERT marketed by Sanofi.
The study met all primary endpoints, demonstrating statistically significant and clinically meaningful improvements in neurological symptoms at 52 weeks compared with patients receiving ERT.
Infilbray is currently under regulatory review in the European Union for GD3. SNY plans to submit additional global filings for the drug in the said indication in the near future.
SNY’s Other Marketed Drugs for Gaucher Disease
Sanofi's commercial portfolio for Gaucher disease includes Cerezyme and Cerdelga, which offer enzyme replacement and oral substrate reduction therapies, respectively. Cerezyme is approved for the treatment of the non-central nervous system symptoms of type 1 Gaucher disease or GD3 in adults and pediatric patients. The GD3 approval was received earlier this year in January. Cerdelga is indicated for type 1 Gaucher disease.
Over the past 30 days, earnings per share estimates for Amneal Pharmaceuticals have increased from $1.03 to $1.06 for 2026. Over the same period, estimates for 2027 earnings per share have risen from $1.16 to $1.21. AMRX’s shares have surged 73.7% year to date.
Amneal Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 27.21%.
Over the past 30 days, loss per share estimates for AC Immune have narrowed from 60 cents to 54 cents for 2026. Over the same period, estimates for 2027 earnings per share have increased from 17 cents to 43 cents. ACIU’s shares have declined 33.1% year to date.
AC Immune’s earnings beat estimates in each of the trailing four quarters, with an average surprise of 37.79%.
Over the past 30 days, loss per share estimates for Adaptive Biotechnologies have narrowed from 55 cents to 39 cents for 2026. Over the same period, estimates for 2027 loss per share have also improved from 17 cents to 3 cents. ADPT’s shares have surged 75.2% year to date.
Adaptive Biotechnologies’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 53.62%.
Image: Bigstock
SNY Wins FDA Approval for Infilbray in Type 3 Gaucher Disease
Key Takeaways
Sanofi (SNY - Free Report) announced that the FDA has granted approval to Infilbray (venglustat), a once-daily oral medicine, to treat patients with type 3 Gaucher disease (GD3). With this approval, the drug becomes the first therapy in the United States to address the progressive neurological symptoms of GD3.
Infilbray is an oral glucosylceramide synthase inhibitor, indicated for the treatment of neurological manifestations of GD3 in adults and pediatric patients weighing at least 15 kg.
Gaucher disease is a rare genetic lysosomal disorder caused by a deficiency of the enzyme glucocerebrosidase, which leads to the buildup of glycosphingolipids in cells, especially in macrophages within the spleen, liver, bone marrow and lungs.Type 3 Gaucher disease is a chronic form of the disorder that affects both the body and the central nervous system.
Year to date, SNY’s shares have risen 1.2% compared with the industry’s 26.7% growth.
Image Source: Zacks Investment Research
Venglustat’s FDA Approval Backed by SNY’s Late-Stage Study
The FDA approval for Infilbray in GD3 is based on positive data from the phase III LEAP2MONO study, which evaluated Infilbray in patients aged 12 years and older with GD3 who were stable on enzyme replacement therapy (ERT) against Cerezyme (imiglucerase), an intravenous ERT marketed by Sanofi.
The study met all primary endpoints, demonstrating statistically significant and clinically meaningful improvements in neurological symptoms at 52 weeks compared with patients receiving ERT.
Infilbray is currently under regulatory review in the European Union for GD3. SNY plans to submit additional global filings for the drug in the said indication in the near future.
SNY’s Other Marketed Drugs for Gaucher Disease
Sanofi's commercial portfolio for Gaucher disease includes Cerezyme and Cerdelga, which offer enzyme replacement and oral substrate reduction therapies, respectively. Cerezyme is approved for the treatment of the non-central nervous system symptoms of type 1 Gaucher disease or GD3 in adults and pediatric patients. The GD3 approval was received earlier this year in January. Cerdelga is indicated for type 1 Gaucher disease.
SNY’s Zacks Rank & Stocks to Consider
SNY currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Amneal Pharmaceuticals (AMRX - Free Report) ,AC Immune (ACIU - Free Report) and Adaptive Biotechnologies (ADPT - Free Report) , carrying a Zacks Rank #2 (Buy) each. You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.
Over the past 30 days, earnings per share estimates for Amneal Pharmaceuticals have increased from $1.03 to $1.06 for 2026. Over the same period, estimates for 2027 earnings per share have risen from $1.16 to $1.21. AMRX’s shares have surged 73.7% year to date.
Amneal Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 27.21%.
Over the past 30 days, loss per share estimates for AC Immune have narrowed from 60 cents to 54 cents for 2026. Over the same period, estimates for 2027 earnings per share have increased from 17 cents to 43 cents. ACIU’s shares have declined 33.1% year to date.
AC Immune’s earnings beat estimates in each of the trailing four quarters, with an average surprise of 37.79%.
Over the past 30 days, loss per share estimates for Adaptive Biotechnologies have narrowed from 55 cents to 39 cents for 2026. Over the same period, estimates for 2027 loss per share have also improved from 17 cents to 3 cents. ADPT’s shares have surged 75.2% year to date.
Adaptive Biotechnologies’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 53.62%.